Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Corticosteroid use poses risk of febrile neutropenia

Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

Publish date:: November 3, 2018

Key clinical point: Risk factors for chemotherapy-induced febrile neutropenia include corticosteroid use and intravenous antibiotics.

Major finding: Corticosteroid use was associated with an increased risk of febrile neutropenia, compared with no corticosteroid use (hazard ratio, 1.53; P less than .01).

Study details: This retrospective study included 15,971 patients with non-Hodgkin lymphoma or five solid tumors.

Disclosures: The study was funded by Amgen. Three of the authors reported being employers and stockholders of Amgen.

Read the article.

Citation:

Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,